| Literature DB >> 19736928 |
Frederick W Goldberg1, Richard A Ward, Steven J Powell, Judit E Debreczeni, Richard A Norman, Nicola J Roberts, Allan P Dishington, Helen J Gingell, Kate F Wickson, Andrew L Roberts.
Abstract
A novel class of 4-pyridinoxy-2-anilinopyridine-based TGF-beta type I receptor (also known as activin-like kinase 5 or ALK5) inhibitors is reported. The binding mode of this scaffold was successfully predicted by analyzing possible docked binding modes of literature inhibitors and novel synthetic ideas. Compounds such as 19 are potent ALK5 inhibitors with good physicochemical and pharmacokinetic properties and thus represent high quality leads for further optimization.Entities:
Mesh：
Substances：
Year: 2009 PMID： 19736928 DOI： 10.1021/jm900807w
Source DB: PubMed Journal: J Med Chem ISSN： 0022-2623 Impact factor: 7.446